Toggle menu

DASH Trial

Start date:
June 2019

Why?

Medications to ‘thin’ the blood can have an unwanted effect on strokes caused by bleeding in the brain. Controlling bleeding is crucial in the first few hours after stroke but there is still uncertainty over the best course of treatment.

 

What?

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

 

https://clinicaltrials.gov/ct2/show/NCT03696121

Research Team

Allan MacRaild

Stroke Lead Research Nurse

Seona Burgess

Senior Stroke Research Nurse

Pat Taylor

Senior Stroke Research Nurse

Rachel O'Brien

Lead Research Nurse

Julia Grahamslaw

Lead Research Nurse

Fiona McCurrach

Senior Research Nurse

More EMERGE Trials

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

Read more

EMERGE Biobank

Developing a bioresource for all emergency presentations

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more

Garfield-VTE Study

Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events